Molecular Biology International

Volume 2014 (2014), Article ID 896068, 9 pages

http://dx.doi.org/10.1155/2014/896068

Research Article

Expression of TPM1, a Novel Sarcomeric Isoform of the TPM1 Gene, in Mouse Heart and Skeletal Muscle

Syamalima Dube, Lauren Panebianco, Amr A. Matoq, Henry N. Chionuma, Christopher R. Denz, Bernard J. Poiesz, and Dipak K. Dube

Department of Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA

Received 25 October 2013; Revised 5 February 2014; Accepted 6 February 2014; Published 24 April 2014

Academic Editor: Jamboor Vishwanatha

Copyright © 2014 Syamalima Dube et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

We have investigated the expression of TPM1α and TPM1κ in mouse striated muscles. TPM1α and TMP1κ were amplified from the cDNA of mouse heart by using conventional RT-PCR. We have cloned the PCR amplified DNA and determined the nucleotide sequences. Deduced amino acid sequences show that there are three amino acid changes in mouse exon 2a when compared with the human TPM1κ. However, the deduced amino acid sequences of human TPM1α and mouse TPM1α are identical. Conventional RT-PCR data as well as qRT-PCR data, calculating both absolute copy number and relative expression, revealed that the expression of TPM1κ is significantly lower compared to TPM1α in both mouse heart and skeletal muscle. It was also found that the expression level of TPM1κ transcripts in mouse heart is higher than it is in skeletal muscle. To the best of our knowledge, this is the first report of the expression of TPM1κ in mammalian skeletal muscle.

1. Introduction

Tropomyosins (TMs) are a family of highly conserved actin binding proteins which are expressed in all eukaryotes from yeast to humans. TMs play a critical role in the control of Ca⁺²-regulated thin filament function in striated muscle contraction. Except for zebrafish, in vertebrates, there are four known tropomyosin (TPM) genes (designated as TPM1, TPM2, TPM3, and TPM4) [1–6]. In zebrafish, six tropomyosin genes have been reported [7]. Each of the TPM genes generates a multitude of tissue and developmental specific isoforms via alternate splicing. TPM1 is known to produce at least ten alternatively spliced transcript variants [8].

In mammals, the predominant striated muscle isoform is TPM1α containing exons 1a, 2b, 3, 4, 5, 6b, 7, 8, and 9a/b, which encode 284 amino acid residues. Our laboratory first reported another striated muscle isoform known as TPM1κ in axolotl heart [9] that contains exons 1a, 2a (instead of exon 2b), 3, 4, 5, 6b, 7, 8, and 9a/b. We also reported the expression of TPM1κ in axolotl skeletal muscle [8], human heart [10], and embryonic chicken heart [11]. In humans, TPM1κ is expressed in both fetal and adult hearts, whereas in chicken both TPM1α and TPM1κ are expressed only in embryonic heart [11]. Interestingly, transgenic mice that overexpressed human TPM1κ, in a cardiac-specific manner, were found to develop a dilated cardiomyopathy-like syndrome [12]. However, it was not clear whether TPM1κ is expressed in normal mouse hearts. Two possible reasons for observing some abnormalities in TG mouse hearts ectopically overexpressing human TPM1κ were that too much TPM1κ is toxic to the mouse cardiomyocyte or that human TPM1κ is variant from its mouse homologue and, for that reason alone, is toxic. Hence, we decided to explore TPM1κ expression in mouse hearts by RT-PCR and sequencing.

In this study, we report the expression of TPM1κ in mouse heart and skeletal muscles. To the best of our knowledge, this is the first report that TPM1κ is expressed in mammalian skeletal muscle. Two different methods were used to quantify the expression of TPM1α and TPM1κ. We determined the absolute copy number as well as relative expression compared to a reference gene (18S rRNA) in mouse heart and skeletal muscle. Unlike in humans [12], the expression level of TPM1κ transcripts in mouse heart is much lower compared to TPM1α. Further, there are three amino acid changes in mouse relative to human TPM1κ.

2. Materials and Methods

Mouse whole heart RNA was procured from Stratagen and ZyAgen; skeletal muscle RNA from BioChain and ZyAgen. Also, we received mouse whole heart and skeletal muscle RNA as a generous gift from Dr. David Wieczroek, University of Cincinnati, Cincinnati, OH. Each of these four sources of RNA came from a single adult mouse.

The quality of RNA was determined by capillary electrophoresis using 2100 Bioanalyzer, Agilent Technologies. The RIN (RNA integrity number) of the RNA samples ranged from 7.2 to 9, indicating that the RNAs we used were of good quality.

2.1. Preparation of cDNA for Conventional RT-PCR

0.5 μg of RNA in a total volume of 40 μL was used for preparing first strand cDNA synthesis with the SuperScriptR II (Life Technologies, Brand Island, NY) and oligodT primer following the manufacturer’s specification. For each PCR amplification, 3 μL of cDNA was used [13, 14]. Nucleotide sequences for the primer pairs for amplification of various mouse genes are given in Table 1.

Table 1: Primer pairs and probes used for amplification and detection of TPM1α and/or TPM1κ.

Name
Name as in Figure 1
Sequences

Mus TPM1 (+)
P1
5′-ATGGACGCCATCAAGAAGAA-3′

Mus TPM1 (−)
P2
5′-TTATATGGAAGTTATATCGTT-3′

Mus TPM1 (+)
P3
5′-CTCAAGGGCACTGAAGATGAA-3′

Mus TPM1 (+)
P4
5′-CTCGAGGAGATCGCAGCG-3′

Mus TPM1 probe
P5
5′-CTGGAGCTGGCGGAGAAAAAGGCC-3′

Mus TPM1 probe
5′-GGCGGAGGACAGCCTCCTGGCTGC-3′

Mus TPM1 UTR (−)
5′-GAGTCTTGGGAGGAGTGAAG-3′

2.2. Conventional RT-PCR, Cloning, and Sequencing of TPM1κ from Heart and Skeletal Muscle

Figure 1 illustrates the pattern of alternative splicing of the two sarcomeric TPM1 isoforms. TPM1α contains exons 1a, 2b, 3, 4, 5, 6b, 7, 8, and 9a/b, whereas TPM1κ has all the same exons except it contains exon 2a instead of exon 2b. The figure also depicts the strategy for amplification of the two TPM1 isoforms. Primer pair P1(+)/P2(−) was used to amplify both TPM1α and TPM1κ. Amplification by the primer pairs P3(+)/P2(−) and P4(+)/P2(−) will yield TPM1α and TPM1κ, respectively. Subsequently, an isoform-specific [32P]-labeled probe was used for southern hybridization of TPM1α or TPM1κ. The sequences of various primer pairs as well as probes are shown in Table 1. We amplified TPM1α and TPM1κ by RT-PCR with cDNA from mouse heart muscle using the mus TPM1α/κ primer pair. The amplified DNA was run on a 1.5% agarose gel and the DNA band of ~850 bp was extracted using MinElute Gel Extraction kit of QIAGEN. The eluted DNA was ligated to T/A cloning vector (Invitrogen) following the manufacturer’s specification as described earlier [10]. The ligation mix was used for transformation of competent one shot E. coli cells (Invitrogen) using the protocol supplied by Invitrogen. Appropriate hybridization positive colonies were picked up from the plates after filter hybridization with [32P]-labeled probe. Exon 2a specific probe was used for TPM1κ and exon 2b specific probe was used for TPM1α. Colonies were grown overnight with LB medium containing appropriate concentration of antibiotic and plasmid DNA was isolated using QIAprep Spin Miniprep kit (QIAGEN). Isolated plasmid DNA was sequenced at the Cornell University DNA sequencing facility (Figure 5).

(a)

(b)

Figure 1: Alternate splicing of the TPM1 gene and exon composition of various TM isoforms. (a) Splicing pattern of the TPM1 gene and the strategy for amplification of TPM1α and TPM1κ. Arrows indicate the primer pairs used for amplification of TPM1α and TPM1κ by RT-PCR and subsequent southern hybridization. The nucleotide sequences of various primer pairs and probes are listed in Table 1. (b) Exon composition of various TPM isoforms.

2.3. cDNA for qRT-PCR

In order to exclude all other isoforms of the TPM1 gene, cDNA was made with a negative primer from exon 9a (5′-CGCTCTCAACGATATGACTT-3′), which is common to both TPM1α and TPM1κ and is absent from other isoforms (Figure 1). 0.5 μg of RNA in a total volume of 40 μL was used for preparing the first strand cDNA synthesis with the SuperScriptR II (Life Technologies, Brand Island, NY) following the manufacturer’s specification.

2.4. Real Time qRT-PCR

Real-time quantitative RT-PCR (qRT-PCR) analysis of cDNA template was performed using the LightCycler 480 real-time PCR system. Reactions were carried out in a 384-well plate using the LightCycler 480 SYBR Green I Master kit (Roche). Briefly, each well contained a total volume of 10 μL, of which 2 μL was cDNA template and 8 μL was SYBR Green mix (5 μL 1x SYBR Green Master mix, 2.8 μL of PCR grade water, and 0.2 μL of 10 μM primer pair). Expression of TPM1 isoforms was determined using primer pairs for TPM1α and TPM1κ, (+)5′-TGGAAGATGAGCTGGTGTCAC-3′/(−)5′-TCAATGACTTTCATGCCTCT-3′, and (+)5′-CTCGAGGAGGACATCGCAGCG-3′/(−)5′-TCAATGACTTTCATGCCTCT-3′, respectively. 18S rRNA was assessed as an internal control with primer pair (+)5′-GTGGAGCGATTTGTCTGGTT-3′/(−)5′-CGCTGA GCCAGTCAGTGTAG-3′. Amplification in the absence of cDNA template was also evaluated to ensure lack of signal due to primer dimerization and extension or carryover. All samples and controls were performed in triplicate. End point melt curve analysis confirmed the presence of a single amplicon in each reaction well. A crossing threshold (CT) value was obtained, corresponding to the fractional number of amplification cycles where the PCR curve reaches a program-defined threshold amount of fluorescence. It is to be noted that qRT-PCR was performed separately with cDNAs prepared from RNA procured from three different sources as mentioned above.

Data were analyzed using both relative and absolute quantification methods. Relative quantification of qRT-PCR data was performed using the delta CT (sample CT minus 18S rRNA CT) and delta delta CT (sample delta CT minus comparator delta CT) methods [15, 16]. A comparative value was calculated using the formula , where “” equals the efficiency of TPM1α or TPM1κ primer pairs. This is similar to the method but corrects for the assumption that the reaction is occurring with 100% efficiency. Efficiencies () were determined using dilution series of TPM1α and TPM1κ plasmid clones with respective isoform-specific primers pairs. The LightCycler 480 software plotted the CT at each concentration against the logarithm of the fold dilution of the clone, generating a linear regression curve that calculated efficiency based on the formula . Efficiencies were 79.05% and 88.42% for TPM1α and TPM1κ, respectively. In instances where TPM1α and TPM1κ were compared within the same cDNA sample, their efficiencies were averaged to equal 83.73%. Efficiency of 18S rRNA was determined by serial dilution of mouse cDNAs generated with exon 9a primer.

For determination of absolute copy number, optical density was taken of mouse TPM1κ and TPM1α TA clones separately using a spectrophotometer. The copy number per volume of clone in solution was determined using the equation number of copies = (ng of plasmid DNA × 6.02 × 10²³)/(bp length of plasmid × 1 × 10⁹ × 650), which was simplified by Andrew Staroscik at the URI Genomics and Sequencing Center. A dilution series of each clone was done for copies of template, which was used to create a standard curve after amplification [8, 14]. For better accuracy, each sample in dilution series was run in triplicate.

2.5. Statistical Analyses

The means, standard deviations, and comparative analyses of each data set for statistical significance were done using paired Student’s -test.

3. Results

3.1. Expression of TPM1α and TPM1κ in Mouse Heart and Skeletal Muscle

For expression analysis, we first employed conventional RT-PCR with cDNA made from total RNA from mouse heart and skeletal muscle. TPM1κ RNA was expressed in both mouse heart and skeletal muscle. To the best of our knowledge, this is the first report of the expression of TPM1κ in mammalian skeletal muscle, albeit at a significantly lower level compared to TPM1α.

Figure 2 depicts the results of conventional RT-PCR analysis of TPM1α and TPM1κ with cDNAs synthesized from mouse heart and skeletal muscle total RNA (provided by Dr. David Wieczroek), using a variety of generic as well as isoform specific primer pairs. Panel (a) in Figure 2 represents the ethidium stained PCR products run on a 1.5% agarose gel. Lanes 1 and 2 show the PCR products amplified from heart cDNA with two different primer pairs, which amplify both TPM1α and TPM1κ. Southern hybridization with TPM1α-specific probe demonstrated stronger signals in both lanes (lanes 1 and 2, panel (b)) compared to hybridization with TPM1κ-specific probe (lanes 1 and 2, panel (c)). The weaker signals in lanes 1 and 2 in panel (c) compared to panel (b) indicate much lower expression level of TPM1κ compared to TPM1α. Lanes 3 and 4 in panel (a) represent the ethidium staining of the PCR products when amplified with TPM1κ or TPM1α-specific primer pairs, respectively. Southern hybridization with TPM1α-specific probe shows a strong hybridization signal (lane 4, panel (b)) with the TPM1α-specific primer pair. A strong hybridization signal was also detected with TPM1κ-specific probe (lane 3, panel (c)) with the TPM1κ-specific primer pair. The results indicate that both TPM1α and TPM1κ RNA are expressed in mouse heart. This was further confirmed by amplification with another TPM1κ-specific primer pair and subsequent southern hybridization with TPM1κ-specific probe (lane 5, panels (a), (b), and (c)). All primer controls were negative (lanes 6, 7, and 8). Lanes 9 and 10 represent the PCR amplicons of mouse skeletal muscle cDNA with two sets of TPM1α/κ primer pairs. Ethidium bromide stained gels indicate a strong expression of TPM1 in skeletal muscle (panel (a)). Hybridization signal with TPM1α-specific probe (panel (b)) versus the TPM1κ-specific probe (panel (c)) indicates a much stronger expression of the former. However, amplification of skeletal muscle cDNA with TPM1κ-specific primer pair (lane 11 in panel (a)) and subsequent hybridization with TPM1κ-specific probe (lane 11 in panel (c)) validate the expression of TPM1κ in mouse skeletal muscle. Similarly, the expression of TPM1α in skeletal muscle was authenticated by the PCR amplification with TPM1α-specific primer pair (lane 12, panel (a)) and by subsequent hybridization with TPM1α-specific probe (lane 12, panel (b)). A much lower expression level of TPM1κ compared to TPM1α in mouse heart and skeletal muscle was further substantiated by qRT-PCR as described below. Similar conventional RT-PCR results were obtained from the RNA procured from Stratagen and Biochain (data not shown).

Figure 2: Expression analysis of TPM1α and TPM1κ RNA in mouse heart and skeletal muscle by RT-PCR. Plate (a) illustrates the ethidium bromide stain. Plate (b) illustrates hybridization with TPM1α probe. Plate (c) illustrates hybridization with TPM1κ probe. Lane 1: heart cDNA amplified with Mus TPM1α/κ-1 (+)/Mus UTR (−). Lane 2: heart cDNA amplified with Mus TPM1α/κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 3: heart cDNA amplified with Mus TPM1κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 4: heart cDNA amplified with TPM1α (+)/Mus TPM1α/κ-2 (−). Lane 5: heart cNDA amplified with Mus TPM1κ-1 (+)/Mus UTR (−). Lane 6: primer control for Mus TPM1α/κ-1 (+)/Mus UTR (−). Lane 7: primer control for Mus TPM1α/κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 8: primer control for Mus TPM1κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 9: skeletal cDNA amplified with Mus TPM1α/κ-1 (+)/Mus UTR (−). Lane 10: skeletal cDNA amplified with Mus TPM1α/κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 11: skeletal cDNA amplified with Mus TPM1κ-1 (+)/Mus TPM1α/κ-2 (−). Lane 12: skeletal cDNA amplified with Mus TPM1α-1 (+)/Mus TPM1α/κ-2 (−).

3.2. Determination of Copy Number of TPM1α and TPM1κ in Mouse Heart and Skeletal Muscles by qRT-PCR

Relative quantification of TPM1α and TPM1κ in mouse heart and skeletal muscles was performed on all sources of RNA. The standard curves for TPM1α and TPM1κ are shown in Figure 3. Our qRT-PCR data for copy number determination indicate that the expression of TPM1κ is much lower in both heart and skeletal muscle compared to TPM1α (Table 2). In relation to cardiac muscle, the data indicate that the level of expression of TPM1α transcripts is significantly higher and the level of TPM1κ is significantly lower in skeletal muscle (Tables 2 and 3).

Table 2: Copy number of TPM1α and TPM1κ in mouse heart and skeletal muscle.

Isoform
Absolute copy number/g of total RNA × 10⁵

Heart
Skeletal muscle

Expt 1
Expt 2
Expt 3
Ave
Expt 1
Expt 2
Expt 3
Ave

TPM1α

TPM1κ

TPM1α : TPM1κ
561
137
367
355
4900
2127
9294
5440

(i) TPM1α heart : TPM1α skeletal muscle, .

(ii) TPM1κ heart : TPM1 skeletal muscle, .

(iii) TPM1α heart : TPM1 heart, .

(iv) TPM1α skeletal muscle : TPM1 skeletal muscle, .

Table 3: Fold changes of TPM1 and TPM1 in heart and skeletal muscle (by copy number).

Ratio of TPM1 in skeletal muscle : heart
Ratio of TPM1 in heart : skeletal muscle

Expt 1
Expt 2
Expt 3
Mean ± SD
Expt 1
Expt 2
Expt 3
Mean ± SD

2.68
4.25
2.15

3.25
3.63
10.0

Figure 3: Quantitative RT-PCR of TPM1α and TPM1κ. Standard curve was derived from amplification of mouse TPM1α and TPM1κ plasmid clones after serial dilution. Copy number of TPM1α and TPM1κ was calculated per microgram of total RNA from mouse heart and skeletal muscle (Table 2).

3.3. Relative Expression of TPM1α and TPM1κ

As the absolute copy number determination revealed that the expression level of TPM1κ is significantly lower in heart and skeletal muscle, we analyzed our results by method using 18S rRNA as the reference gene to determine the relative expression of TPM1α and TPM1κ. Melt curve data presented in Figure 4(a) show different unique melting temperatures for TPM1α (left) and TPM1κ (right). Also, agarose gel electrophoresis of the PCR amplified DNA for TPM1α or TPM1κ shows a single band for both of them (Figure 4(b)). Hence, each primer pair recognizes only TPM1α or TPM1κ amplified DNA.

(a)

(b)

Figure 4: Melt curves of SYBER green PCR and the agarose gel electrophoresis of PCR products with ethidium bromide staining. (a) Melt curves for amplified TPM1α and TPM1κ DNA. The peaks melting at one different temperature specific for TPM1α or TPM1κ demonstrate specific amplification of just one product for TPM1α and TPM1κ. The multiple curves represent the products from multiple replicates of the RT-PCR assay. (b) Agarose gel of PCR products with ethidium bromide staining to demonstrate amplification of a single product for TPM1α, TPM1κ, and 18S rRNA amplification. Lane 1 is heart, lane 2 is skeletal muscle, and lane 3 is for the respective primer control.

Figure 5: Nucleotide and deduced amino acid sequences of mouse TPM1κ. Nucleotide sequence exon 2a is underlined and italicized. The generic primer pair that amplifies both TPM1α and TPM1κ is underlined. Two nucleotides in TPM1κ in exons 1a and 4 were found to be different from the published sequence. TPM1α sequence is made bold and underlined. These changes do not alter the amino acid sequences. Deduced protein/amino acid sequences are on the top of the nucleotide sequences. Symbol of each amino acid residue is placed on the top of the third nucleotide of each codon. Amino acid residues in exon 2a that are different form human TPM1κ are underlined with double lines.

The data in Table 4 validate our previous findings that expression of TPM1κ is significantly lower than TPM1α in mouse heart and skeletal muscle. The fold changes of TPM1α/TPM1κ are significantly higher in skeletal muscle suggesting the higher expression level of TPM1κ in heart as concluded from the absolute copy number data (Table 2). We analyzed our qRT-PCR data by . The results support our conclusion that TPM1α expression is much higher in mouse skeletal versus heart muscle; and the level of expression of TPM1κ is higher in mouse heart versus skeletal muscle (Table 5).

Table 4: qRT-PCR for mouse heart and skeletal muscle.

Muscle type
Fold differences of TPM1/TPM1κ

()*
Average

Experiment
Experiment
Experiment

Heart
650.05
843.08
879.13

Skeletal muscle
5372.22
4374.45
6292.72

TPM1 heart : TPM1 heart, ; TPM1 skeletal muscle : TPM1 skeletal muscle . TPM1/TPM1 heart : TPM1/TPM1 skeletal muscle, .

Table 5: Fold changes of TPM1 and TPM1 in heart and skeletal muscle ().

Ratio of TPM1 in skeletal muscle : heart*
Ratio of TPM1 in heart : skeletal muscle*

Expt 1
Expt 2
Expt 3
Average ± S.D.
Expt 1
Expt 2
Expt 3
Average ± S.D.

2.55
1.7
1.79

3.38
5.88

10.04

TPM1 skeletal muscle : TPM1 heart, ; TPM1 heart : TPM1 skeletal muscle, .

3.4. DNA Sequencing of TPM1α and TPM1κ cDNAs from Mouse Heart and Skeletal Muscle

cDNA sequencing confirmed the expression of both TPM1α and TPM1κ expression in mouse heart and skeletal muscle. Nucleotide and the deduced amino acid sequences of mouse TPM1α were identical with the published sequence (accession number NM_001164248.1) (data not shown). Also, the nucleotide sequences of mouse TPM1α and TPM1κ as depicted in Figure 5 are identical except for exon 2. As predicted, TPM1α contains exon 2b, but TPM1κ has exon 2a. The deduced amino acid sequences of mouse and human exon 2b of the TPM1 gene are identical. The deduced amino acid sequences of exon 2a of mouse TPM1κ and the published exon 2a sequences in mouse TPM1β (smooth muscle TPM1 isoform) (NM_001164249.1) are also identical. However, some differences were noted when comparing the deduced amino acid sequences of mouse exon 2a with human TPM1 2a (Figure 6). Amino acid residues ⁷²E and ⁷⁴A in humans are replaced by ⁷²D and ⁷⁴T in mouse TPM1κ, respectively.

Figure 6: Alignment of the amino acid sequences of TPM1 exon 2a or 2b from various species. The top 4 sequences are 2a and the bottom four sequences are 2b. human (Hu), mouse (Mus), axolotl (ax), and chicken (Chi) sequences are shown. The underlined sequence in human TPM1κ was used to develop the antibody utilized to detect TPM1κ protein. The amino acid residue numbers are as shown. Conserved sequences are indicated by the (·).

However, the most notable difference is at amino acid residue 52. In humans, it is valine, whereas in mouse it is alanine. This amino acid residue is in the middle of the 15-mer peptide (KEKLLRVSEDERDRV) that was used as the antigen for developing antibody against human TPM1κ [12]. This alteration may cause a lower affinity of this antibody towards mouse TPM1κ protein. In order to evaluate the expression of TPM1κ protein, in this study, we carried out western blot analysis with isolated myofibrils from mouse heart and skeletal muscle using the human TPM1κ-specific antibodies. The antibodies against human protein showed several nonspecific bands with mouse heart and skeletal muscle extracts. The western results are not convincing as to whether TPM1κ protein is expressed in mouse striated muscle.

4. Discussion

We first detected and sequenced TPM1κ from the heart of the Mexican axolotl [9]. Both the RNA and protein of this sarcomeric TM isoform is expressed in both heart and skeletal muscle in axolotl [8]. Subsequently, we reported the expression of TPM1κ transcripts and protein in human heart but not in skeletal muscle [10]. Also, TPM1κ along with TPM1α is expressed in embryonic chicken heart but not in skeletal muscle [11]. However, the transcripts of neither TM isoform could be detected in adult chicken heart and skeletal muscle [11]. Our present study clearly demonstrates that TPM1κ RNA is expressed in adult mouse heart and skeletal muscle. Unfortunately, because an anti-mouse TPM1κ antibody is not available, we cannot comment on protein expression. The levels of TPM1α and TPM1κ RNA in axolotl heart and skeletal muscle and human heart muscle are comparable. However, the level of expression of TPM1κ protein compared to TPM1α protein is very low. This suggests a differential translational efficiency for the transcripts of the two isoforms. Hence, we cannot speculate about levels of TPM1κ protein in murine striated muscles.

Interestingly, the expression of TPM1κ protein is increased in hearts in dilated cardiomyopathy (DCM) and heart failure human patients. However, we do not know whether this increase in TPM1κ is the cause or consequence of the cardiac disease [12]. The immunohistochemical analyses with TPM1κ antibody show that it is incorporated into axolotl cardiac and skeletal myofibrils and into human cardiac myofibrils [8]. Currently, the exact role TPM1κ protein plays in cardiac contractility is unclear. We have shown that transfection of antisense TPM1κ oligonucleotides into embryonic axolotl hearts inhibits the cardiac contractility in situ and also disarrays the cardiac myofibrils [17].

Herein, for expression analysis of TPM1κ transcripts we performed both conventional and real-time RT-PCR with total RNA from mouse heart and skeletal muscle using isoform specific primer pairs. RT-PCR data show the expression pattern of TPM1α and TPM1κ in mouse heart and skeletal muscle (Figure 4). We quantified the absolute copy number of TPM1α and TPM1κ expressed in heart and skeletal muscle. The results presented in Tables 2 and 3 show the higher copy number of TPM1κ expressed in mouse heart compared to skeletal muscle. Total copy number of TPM1α is higher in skeletal muscle. Hence, the difference in the ratio of copy numbers of TPM1α : TPM1κ is even more pronounced between the two tissues. The expression of TPM1α transcript is ~2- to 3-fold higher in skeletal muscle compared to heart. On the contrary, the expression of TPM1κ is ~3-fold higher in heart compared to mouse skeletal muscle. The real-time PCR (RT-PCR) results using copy number procedure is also reflected from the qRT-PCR data using method where we have used 18S rRNA as the reference gene (Table 4). We conclude that expression level of TPM1κ transcripts is higher in mouse heart compared to skeletal muscle. Further, the expression level of TPM1κ compared to TPM1α is significantly lower in both heart and skeletal muscle. Our analysis of qRT-PCR data by method also supports the similar conclusions (Table 5). It is worth mentioning that TPM1α expressed per μg of total RNA is considerably higher in skeletal muscle relative to heart muscle in axolotl as well [8]. We do not know whether this would be a consistent finding in all vertebrates. A higher expression level of TPM1α in skeletal muscle could be attributed to the higher requirement of TPM1α protein in skeletal muscle or due to the higher turnover of TPM1α RNA or protein in skeletal muscle. An altered dynamicity of tropomyosin in heart versus skeletal muscle may contribute to higher concentration of TPM1α mRNA observed in skeletal muscle. Wang et al. [18] compared the recovery rates of mature myofibrils in avian cardiomyocytes and skeletal muscle cells transfected with avian TPM1α or TPM1κ after photobleaching and noted the marked decreased rates of recoveries of both TPM1 isoforms in skeletal muscles compared with myofibrils in cardiomyocytes. The results suggest a lower dynamicity of tropomyosin in skeletal muscle. Hence, one can speculate that more transcripts of tropomyosin accumulate in the skeletal muscles cells or the transcriptional efficiency of the TPM1 gene is significantly higher in skeletal muscle cells. Further studies are warranted for proposing a definitive explanation.

The deduced amino acid sequences show that three amino acid residues in exon 2a (Figure 6) are different from that of human sequences. In human TPM1κ, the 52nd amino acid residue is valine whereas it is alanine in mouse TPM1κ. This alteration may contribute to a lower affinity of the TPM1κ antibody [8, 12] that we used for western blot analysis to detect the expression of TPM1κ protein in mouse heart and skeletal muscle. There is such precedence in tropomyosin literature. An antibody, ARG1, targeted toward residues 214–226 (Tyr-Ser-Gln-Lys-Glu-Asp-Arg-Tyr-Glu-Glu-Glu-Ile-Lys) of human TPM1α can recognize human TPM1α but not Rat TPM1α. The amino acid sequence of human TPM1α differs from that of rat TPM1α by an Arg-to-Lys amino acid exchange in position 220 [19].

In addition, amino acid residues ⁷²E and ⁷⁴A in humans are replaced by ⁷²D and ⁷⁴T, respectively, in mouse TPM1κ (Figure 6). Overexpression of human TPM1κ protein in a cardiac-specific manner leads to the development of DCM in transgenic mice [12, 20]. It is to be noted that several missense mutations in exon 2b in TPM1α have been implicated in human DCM [21]. Olson et al. identified two mutations in exon 2b of the TPM1 gene that altered two very conserved amino acids and also reversed the charges on the surface of tropomyosin [21]. The differences of the amino acid residues in exon 2a of human TPM1κ and mouse TPM1κ (Figure 6) do not alter the net charges. At this juncture, we are unsure whether the absolute overexpression of human TPM1κ and/or its altered exon 2a protein relative to the mouse sequence explains the DCM-like phenotype observed in transgenic mice [12]. Obviously, one should consider creating transgenic mice with mouse TPM1κ to better understand the physiological relevance of TPM1κ protein.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The work in this laboratory was supported by Grants from American Heart Association (both National and New York State affiliate), CNY Children’s Miracle Network, Syracuse, NY, Grants from Golisano Children’s Hospital, Syracuse, NY, and funding from College of Health Professionals, Upstate Medical University, Syracuse, to Dipak K. Dube and the Barbara Kopp Cancer Research Fund to Bernard J. Poiesz.

References

P. Gunning, G. O'Neill, and E. Hardeman, “Tropomyosin-based regulation of the actin cytoskeleton in time and space,” Physiological Reviews, vol. 88, no. 1, pp. 1–35, 2008.

J. P. Lees-Miller and D. M. Helfman, “The molecular basis for tropomyosin isoform diversity,” BioEssays, vol. 13, no. 9, pp. 429–437, 1991.

S. V. Perry, “Vertebrate tropomyosin: distribution, properties and function,” Journal of Muscle Research and Cell Motility, vol. 22, no. 1, pp. 5–49, 2001.

K. Pieples and D. F. Wieczorek, “Tropomyosin 3 increases striated muscle isoform diversity,” Biochemistry, vol. 39, no. 28, pp. 8291–8297, 2000.

M. F. Pittenger, J. A. Kazzaz, and D. M. Helfman, “Functional properties of non-muscle tropomyosin isoforms,” Current Opinion in Cell Biology, vol. 6, no. 1, pp. 96–104, 1994.

D. F. Wieczorek, “Regulation of alternatively spliced α-tropomyosin gene expression by nerve extract,” Journal of Biological Chemistry, vol. 263, no. 21, pp. 10456–10463, 1988.

G. Schevzov, S. P. Whittaker, T. Fath, J. J. Lin, and P. W. Gunning, “Tropomyosin isoforms and reagents,” Bioarchitecture, vol. 1, pp. 135–164, 2011.

A. Thomas, S. Rajan, H. L. Thurston et al., “Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscle,” Journal of Cellular Biochemistry, vol. 110, no. 4, pp. 875–881, 2010.

E. A. Luque, B. J. Spinner, S. Dube, D. K. Dube, and L. F. Lemanski, “Differential expression of a novel isoform of α-tropomyosin in cardiac and skeletal muscle of the Mexican axolotl (Ambystoma mexicanum),” Gene, vol. 185, no. 2, pp. 175–180, 1997.

C. R. Denz, A. Narshi, R. W. Zajdel, and D. K. Dube, “Expression of a novel cardiac-specific tropomyosin isoform in humans,” Biochemical and Biophysical Research Communications, vol. 320, no. 4, pp. 1291–1297, 2004.

R. W. Zajdel, C. R. Denz, S. Lee et al., “Identification, characterization, and expression of a novel α-tropomyosin isoform in cardiac tissues in developing chicken,” Journal of Cellular Biochemistry, vol. 89, no. 3, pp. 427–439, 2003.

S. Rajan, G. Jagatheesan, C. N. Karam et al., “Molecular and functional characterization of a novel cardiac-specific human tropomyosin isoform,” Circulation, vol. 121, no. 3, pp. 410–418, 2010.

C. R. Denz, C. Zhang, P. Jia et al., “Absence of mutation at the 50-upstream promoter region of the TPM4 gene from cardiac mutant axolotl (Ambystoma mexicanum),” Cardiovascular Toxicology, vol. 11, no. 3, pp. 235–243, 2011.

H. L. Thurston, S. Prayaga, A. Thomas et al., “Expression of Nkx2.5 in wild type, cardiac mutant, and thyroxine-induced metamorphosed hearts of the mexican axolotl,” Cardiovascular Toxicology, vol. 9, no. 1, pp. 13–20, 2009.

M. W. Pffaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, pp. 2002–2007, 2001.

K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.

R. W. Zajdel, C. R. Denz, A. Narshi, S. Dube, and D. K. Dube, “Anti-sense-mediated inhibition of expression of the novel striated tropomyosin isoform TPM1κ disrupts myofibril organization in embryonic axolotl hearts,” Journal of Cellular Biochemistry, vol. 95, no. 4, pp. 840–848, 2005.

J. Wang, J. M. Sanger, S. Kang et al., “Ectopic expression and dynamics of TPM1α and TPM1κ in myofibrils of avian myotubes,” Cell Motility and the Cytoskeleton, vol. 64, no. 10, pp. 767–776, 2007.

D. Wernicke, C. Thiel, C. M. Duja-Isac et al., “α-tropomyosin mutations Asp175 Asn and Glu180 Gly affect cardiac function in transgenic rats in different ways,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 287, no. 3, pp. R685–R695, 2004.

C. N. Karam, C. M. Warren, S. Rajan, P. P. de Tombe, D. F. Wieczorek, and R. J. Solaro, “Expression of tropomyosin-κ induces dilated cardiomyopathy and depresses cardiac myofilament tension by mechanisms involving cross-bridge dependent activation and altered tropomyosin phosphorylation,” Journal of Muscle Research and Cell Motility, vol. 31, no. 5-6, pp. 315–322, 2011.

T. M. Olson, N. Y. Kishimoto, F. G. Whitby, and V. V. Michels, “Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 4, pp. 723–732, 2001.